Vascular endothelial growth factor plus epidermal growth factor receptor dual targeted therapy in metastatic colorectal cancer: Synergy or antagonism?

Journal of Oncology

Volumn , Issue , 2009, Pages

  Marshall, John L ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; VANDETANIB; VASCULOTROPIN;

ADD ON THERAPY; ARTERY THROMBOSIS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DRUG ANTAGONISM; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; INFECTION; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; RASH; REVIEW; SENSORY NEUROPATHY; SKIN MANIFESTATION; SKIN TOXICITY; VENOUS THROMBOEMBOLISM;

EID: 73449100517     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2009/937305     Document Type: Review

References (61)

1. Jemal A., Siegel R., Ward E., Cancer statistics, 2009 CA: A Cancer Journal for Clinicians 2009 59 4 225 249
2. Rodriguez J., Zarate R., Bandres E., Combining chemotherapy and targeted therapies in metastatic colorectal cancer World Journal of Gastroenterology 2007 13 44 5867 5876
3. Berlin J., Posey J., Tchekmedyian S., Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer Clinical Colorectal Cancer 2007 6 6 427 432 (Pubitemid 46658516)
4. Sobrero A. F., Maurel J., Fehrenbacher L., EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer Journal of Clinical Oncology 2008 26 14 2311 2319
5. Cunningham D., Humblet Y., Siena S., Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer The New England Journal of Medicine 2004 351 4 337 345
6. Van Cutsem E., Khne C.-H., Hitre E., Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer The New England Journal of Medicine 2009 360 14 1408 1417
7. Peeters M., Wilson G., Ducreux M., Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): pooled safety results Journal of Clinical Oncology 2008 26 15S 4064
8. Hecht J. R., Patnaik A., Berlin J., Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer Cancer 2007 110 5 980 988 (Pubitemid 47312862)
9. Van Cutsem E., Peeters M., Siena S., Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer Journal of Clinical Oncology 2007 25 13 1658 1664
10. Van Cutsem E., Siena S., Humblet Y., An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy Annals of Oncology 2008 19 1 92 98
11. Jonker D. J., OCallaghan C. J., Karapetis C. S., Cetuximab for the treatment of colorectal cancer The New England Journal of Medicine 2007 357 20 2040 2048
12. Giantonio B. J., Catalano P. J., Meropol N. J., Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200 Journal of Clinical Oncology 2007 25 12 1539 1544
13. Hurwitz H., Fehrenbacher L., Novotny W., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer The New England Journal of Medicine 2004 350 23 2335 2342
14. Kabbinavar F. F., Schulz J., McCleod M., Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial Journal of Clinical Oncology 2005 23 16 3697 3705
15. Saltz L. B., Meropol N. J., Loehrer P. J. Sr., Needle M. N., Kopit J., Mayer R. J., Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor Journal of Clinical Oncology 2004 22 7 1201 1208
16. Downward J., Targeting RAS signalling pathways in cancer therapy Nature Reviews Cancer 2003 3 1 11 22
17. Amado R. G., Wolf M., Peeters M., Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer Journal of Clinical Oncology 2008 26 10 1626 1634
18. Benvenuti S., Sartore-Bianchi A., Di Nicolantonio F., Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies Cancer Research 2007 67 6 2643 2648
19. Khambata-Ford S., Garrett C. R., Meropol N. J., Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab Journal of Clinical Oncology 2007 25 22 3230 3237
20. Livre A., Bachet J.-B., Boige V., KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab Journal of Clinical Oncology 2008 26 3 374 379
21. Karapetis C. S., Khambata-Ford S., Jonker D. J., K-ras mutations and benefit from cetuximab in advanced colorectal cancer The New England Journal of Medicine 2008 359 17 1757 1765
22. Tejpar S., Peeters M., Humblet Y., Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): the EVEREST experience (preliminary data) Journal of Clinical Oncology 2008 26 15S 4001
23. Cervantes T., Macarulla T., Martinelli E., Correlation of KRAS status (wild type [wt] vs. mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab + FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) Journal of Clinical Oncology 2008 26 4129
24. Di Fiore F., Van Cutsem E., Laurent-Puig P., Role of KRAS mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: analysis of 281 individual data from published series Journal of Clinical Oncology 2008 26 4035
25. Finocchiaro G., Cappuzzo F., Jnne P. A., EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer Journal of Clinical Oncology 2007 25 18S 4021
26. Bokemeyer C., Bondarenko I., Makhson A., Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer Journal of Clinical Oncology 2009 27 5 663 671
27. Herbst R. S., Johnson D. H., Mininberg E., Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer Journal of Clinical Oncology 2005 23 11 2544 2555
28. Ciardiello F., Bianco R., Damiano V., Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells Clinical Cancer Research 2000 6 9 3739 3747 (Pubitemid 30694960)
29. Shaheen R. M., Ahmad S. A., Liu W., Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors British Journal of Cancer 2001 85 4 584 589
30. Jung Y. D., Mansfield P. F., Akagi M., Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model European Journal of Cancer 2002 38 8 1133 1140
31. Petit A. M., Rak J., Hung M.-C., Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors The American Journal of Pathology 1997 151 6 1523 1530
32. Ciardiello F., Caputo R., Damiano V., Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase Clinical Cancer Research 2003 9 4 1546 1556
33. Saltz L. B., Lenz H.-J., Kindler H. L., Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study Journal of Clinical Oncology 2007 25 29 4557 4561
34. Pitot H. C., Wender D. B., OConnell M. J., Phase II trial of irinotecan in patients with metastatic colorectal carcinoma Journal of Clinical Oncology 1997 15 8 2910 2919
35. Shimada Y., Yoshino M., Wakui A., Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer Journal of Clinical Oncology 1993 11 5 909 913
36. Meyerhardt J. A., Stuart K., Fuchs C. S., Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastastic colorectal cancer Annals of Oncology 2007 18 7 1185 1189
37. Giantonio B. J., Levy D. E., ODwyer P. J., Meropol N. J., Catalano P. J., Benson A. B. III, A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200 Annals of Oncology 2006 17 9 1399 1403
38. Saltz L. B., Clarke S., Daz-Rubio E., Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study Journal of Clinical Oncology 2008 26 12 2013 2019
39. Hainsworth J., Herbst R., A phase III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy of bevacizumab (Avastin) in combination with erlotinib (Tarceva) compared with erlotinib alone for treatment of advanced non-small cell lung cancer after failure of standard first-line chemotherapy (BETA) Journal of Thoracic Oncology 2008 3 11 S302
40. Cohen E. E., Davis D. W., Karrison T. G., Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study The Lancet Oncology 2009 10 3 247 257
41. Kim E. S., Herbst R. S., Moon J., S0536: SWOG phase II trial of carboplatin (C), paclitaxel (P), cetuximab (CX) and bevacizumab (B) followed by cetuximab and bevacizumab in advanced non-small cell lung cancer (NSCLC) Journal of Thoracic Oncology 2008 3 11 S266
42. Hecht J. R., Dual EGFR/VEGF: asked and answered, or did we ask the wrong question? CMP Medica LLC, October 2008, http://www.cancernetwork.com/cme/ article/10165/1163036?pageNumber=1
43. Hecht J. R., Mitchell E., Chidiac T., A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer Journal of Clinical Oncology 2009 27 5 672 680
44. de Gramont A., Figer A., Seymour M., Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer Journal of Clinical Oncology 2000 18 16 2938 2947
45. Douillard J. Y., Cunningham D., Roth A. D., Irinotecan combined with fluorouracil compared with fluorouracil alone. as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial The Lancet 2000 355 9209 1041 1047
46. Tournigand C., Andr T., Achille E., FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study Journal of Clinical Oncology 2004 22 2 229 237
47. Tol J., Koopman M., Cats A., Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer The New England Journal of Medicine 2009 360 6 563 572
48. Andreyev H. J. N., Norman A. R., Cunningham D., Kirsten ras mutations in patients with colorectal cancer: the RASCAL II study British Journal of Cancer 2001 85 5 692 696
49. Bazan V., Migliavacca M., Zanna I., Specific codon 13 K- ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K- ras mutations are associated with mucinous histotype Annals of Oncology 2002 13 9 1438 1446
50. Esteller M., Gonzlez S., Risques R. A., K- ras and p16 aberrations confer poor prognosis in human colorectal cancer Journal of Clinical Oncology 2001 19 2 299 304
51. Zhang W., Yang D., Capanu M., Pharmacogenomic analysis of a randomized phase II trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer Journal of Clinical Oncology 2007 25 18S 4128
52. Spindler K.-L. G., Nielsen J. N., Ornskov D., Brandslund I., Jakobsen A., Epidermal growth factor (EGF) A61G polymorphism and EGF gene expression in normal colon tissue from patients with colorectal cancer Acta Oncologica 2007 46 8 1113 1117
53. Graziano F., Ruzzo A., Loupakis F., Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer Journal of Clinical Oncology 2008 26 9 1427 1434
54. Cohn A., Smith D. A., Neubauer M. A., Panitumumab (pmab) regimen evaluation in colorectal cancer to estimate primary response to treatment (PRECEPT): effect of KRAS mutation status on second-line treatment (tx) with pmab and FOLFIRI Journal of Clinical Oncology 2008 26 15S 4127
55. Erbitux0x000AE (cetuximab), Full Prescribing Information. Bristol-Myers Squibb Company, Princeton, NJ, USA, 2008
56. Di Nicolantonio F., Martini M., Molinari F., Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer Journal of Clinical Oncology 2008 26 35 5705 5712
57. Razis E., Briasoulis E., Vrettou E., Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study BMC Cancer 2008 8, article 234
58. Tol J., Nagtegaal I. D., Punt C. J. A., BRAF mutation in metastatic colorectal cancer The New England Journal of Medicine 2009 361 1 98 99
59. Rajagopalan H., Bardelli A., Lengauer C., Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status Nature 2002 418 6901 934
60. Venook A. P., Blanke C. D., Niedzwiecki D., Cancer and leukemia group b/southwest oncology group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma Clinical Colorectal Cancer 2005 5 4 292 294
61. Segal N. H., Reidy-Lagunes D., Capanu M., Phase II study of bevacizumab in combination with cetuximab plus irinotecan in irinotecan-refractory colorectal cancer (CRC) patients who have progressed on a bevacizumab-containing regiment (the BOND 2.5 study) Journal of Clinical Oncology 2009 27 15S 4087